Tat-mediated peptide intervention in analgesia and anesthesia

Drug Development Research

Volumn 71, Issue 2, 2010, Pages 99-105

  Tao, Feng ^a   Johns, Roger A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Minimum alveolar anesthetic concentration; Pain modulation; Protein transduction domain; Protein protein interaction

Indexed keywords

ARGININE; HALOTHANE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HYBRID PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN TYROSINE KINASE; SCAFFOLD PROTEIN; TRANSACTIVATOR PROTEIN;

ANALGESIA; ANESTHESIA; CHRONIC PAIN; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; HYPERALGESIA; IN VIVO STUDY; INFLAMMATION; ISCHEMIA; NEOPLASM; NONHUMAN; PAIN THRESHOLD; PROTEIN PROTEIN INTERACTION; REVIEW; SPINAL CORD;

EID: 77951571903     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20331     Document Type: Review

References (79)

1. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. 2002. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 298:846-850. (Pubitemid 35231541)
2. Amand HL, Fant K, Norden B, Esbjorner EK. 2008. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem Biophys Res Commun 371:621-625.
3. Becker-Hapak M, McAllister SS, Dowdy SF. 2001. TAT-mediated protein transduction into mammalian cells. Methods 24:247-256. (Pubitemid 32846431)
4. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. 2006. The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci 27:311-319. (Pubitemid 43143256)
5. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J. 2002. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22:5423-5431.
6. Christopherson KS, Hillier BJ, Lim WA, Bredt DS. 1999. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem 274:27467-27473. (Pubitemid 129527789)
7. Chung SK, Maiti KK, Lee WS. 2008. Recent advances in cell-penetrating, non-peptide molecular carriers. Int J Pharm 354:16-22. (Pubitemid 351400324)
8. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. 2003. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278:35109-35114.
9. Del GV, MacKenzie JA, Payne RM. 2003. Targeting proteins to mitochondria using TAT. Mol Genet Metab 80:170-180.
10. Del GV, Payne RM. 2003. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 7:720-730.
11. Denicourt C, Dowdy SF. 2003. Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol Sci 24:216-218. (Pubitemid 36588866)
12. Frankel AD, Pabo CO. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193.
13. + exchanger inhibitors on subcellular localisation of endocytic organelles and intracellular dynamics of protein transduction domains HIV-TAT peptide and octaarginine. J Control Release 116:247-254.
14. Fuchs SM, Raines RT. 2004. Pathway for polyarginine entry into mammalian cells. Biochemistry 43:2438-2444. (Pubitemid 38327839)
15. Futaki S. 2006. Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 84:241-249.
16. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. 2001. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836-5840. (Pubitemid 37385738)
17. Futaki S, Goto S, Suzuki T, Nakase I, Sugiura Y. 2003. Structural variety of membrane permeable peptides. Curr Protein Pept Sci 4:87-96. (Pubitemid 36834008)
18. Futaki S, Nakase I, Tadokoro A, Takeuchi T, Jones AT. 2007. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans 35:784-787. (Pubitemid 47310368)
19. Garry MG, Malik S, Yu J, Davis MA, Yang J. 2000. Knock down of spinal NMDA receptors reduces NMDA and formalin evoked behaviors in rat. NeuroReport 11:49-55. (Pubitemid 30053388)
20. Goncalves E, Kitas E, Seelig J. 2005. Binding of oligoarginine to membrane lipids and heparan sulfate: structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry 44:2692-2702. (Pubitemid 40279574)
21. Goun EA, Pillow TH, Jones LR, Rothbard JB, Wender PA. 2006. Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. Chembiochem 7:1497-1515.
22. Green M, Loewenstein PM. 1988. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55:1179-1188. (Pubitemid 19020070)
23. Gump JM, Dowdy SF. 2007. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 13:443-448.
24. Gupta B, Levchenko TS, Torchilin VP. 2005. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57:637-651. (Pubitemid 40255564)
25. Gupta B, Torchilin VP. 2006. Transactivating transcriptional activator-mediated drug delivery. Expert Opin Drug Deliv 3:177-190. (Pubitemid 43338090)
26. Harada H, Kizaka-Kondoh S, Hiraoka M. 2006. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 13:16-26.
27. Herce HD, Garcia AE. 2007. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 104:20805-20810.
28. Jarver P, Langel U. 2006. Cell-penetrating peptides - a brief introduction. Biochim Biophys Acta 1758:260-263.
29. Joliot A, Prochiantz A. 2004. Transduction peptides: from technology to physiology. Nat Cell Biol 6:189-196.
30. Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SM, Newham P, Lindsay MA. 2005. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 145:1093-1102. (Pubitemid 43079982)
31. Kaplan IM, Wadia JS, Dowdy SF. 2005. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102:247-253.
32. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
33. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. 1995. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269:1737-1740.
34. Langer R. 2001. Drug delivery. Drugs on target. Science 293:58-59.
35. Lindgren M, Hallbrink M, Prochiantz A, Langel U. 2000. Cell-penetrating peptides. Trends Pharmacol Sci 21:99-103.
36. Liu XJ, Gingrich JR, Vargas-Caballero M, Dong YN, Sengar A, Beggs S, Wang SH, Ding HK, Frankland PW, Salter MW. 2008. Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nat Med 14:1325-1332.
37. Luft FC. 2003. Transducing proteins to manipulate intracellular targets. J Mol Med 81:521-523.
38. Lundberg M, Johansson M. 2002. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 291:367-371. (Pubitemid 34694414)
39. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ. 1992. Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res 598:271-278. (Pubitemid 23013070)
40. Moy P, Daikh Y, Pepinsky B, Thomas D, Fawell S, Barsoum J. 1996. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol Biotechnol 6:105-113.
41. Murriel CL, Dowdy SF. 2006. Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv 3:739-746.
42. Myou S, Leff AR, Myo S, Boetticher E, Tong J, Meliton AY, Liu J, Munoz NM, Zhu X. 2003a. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J Exp Med 198:1573-1582.
43. Myou S, Zhu X, Myo S, Boetticher E, Meliton AY, Liu J, Munoz NM, Leff AR. 2003b. Blockade of airway inflammation and hyperresponsiveness by HIV-TAT-dominant negative Ras. J Immunol 171:4379-4384.
44. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. 1998. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4:1449-1452.
45. Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, Takehashi M, Tanaka S, Ueda K, Simpson JC, Jones AT, Sugiura Y, Futaki S. 2004. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 10:1011-1022.
46. Nakase I, Tadokoro A, Kawabata N, Takeuchi T, Katoh H, Hiramoto K, Negishi M, Nomizu M, Sugiura Y, Futaki S. 2007. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 46:492-501.
47. Nakase I, Takeuchi T, Tanaka G, Futaki S. 2008. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev 60:598-607.
48. Ragin AD, Morgan RA, Chmielewski J. 2002. Cellular import mediated by nuclear localization signal Peptide sequences. Chem Biol 9:943-948.
49. Rapoport M, Saada A, Elpeleg O, Lorberboum-Galski H. 2008. TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther 16:691-697.
50. Rapoport M, Lorberboum-Galski H. 2009. TAT-based drug delivery system - new directions in protein delivery for new hopes? Expert Opin Drug Deliv 6:453-463.
51. Ren K, Hylden JL, Williams GM, Ruda MA, Dubner R. 1992. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation. Pain 50:331-344.
52. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. 2003. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585-590.
53. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. 2005. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280:15300-15306.
54. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. 2000. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6:1253-1257.
55. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. 2004. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 126:9506-9507.
56. Sakai N, Takeuchi T, Futaki S, Matile S. 2005. Direct observation of anion-mediated translocation of fluorescent oligoarginine carriers into and across bulk liquid and anionic bilayer membranes. Chembiochem 6:114-122.
57. Schwarze SR, Dowdy SF. 2000. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21:45-48.
58. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-1572.
59. Snyder EL, Dowdy SF. 2005. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2:43-51.
60. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. 2002. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 277:2437-2443.
61. Tao F, Johns RA. 2008. Effect of disrupting N-methyl-D-aspartate receptor-postsynaptic density protein-95 interactions on the threshold for halothane anesthesia in mice. Anesthesiology 108:882-887.
62. Tao F, Su Q, Johns RA. 2008. Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice. Mol Ther 16:1776-1782.
63. Tao F, Tao YX, Gonzalez JA, Fang M, Mao P, Johns RA. 2001. Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats. NeuroReport 12:3251-3255.
64. Tao F, Tao YX, Mao P, Johns RA. 2003. Role of postsynaptic density protein-95 in the maintenance of peripheral nerve injury-induced neuropathic pain in rats. Neuroscience 117:731-739.
65. Tao YX, Huang YZ, Mei L, Johns RA. 2000. Expression of PSD-95/SAP90 is critical for N-methyl-D-aspartate receptor-mediated thermal hyperalgesia in the spinal cord. Neuroscience 98:201-206.
66. Torchilin VP. 2008a. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90:604-610.
67. Torchilin VP. 2008b. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548-558.
68. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. 2001. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 98:8786-8791.
69. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B, D'Souza GG. 2003. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100:1972-1977.
70. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. 2006. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 20:1775-1784.
71. Vives E, Brodin P, Lebleu B. 1997. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-16017.
72. Wadia JS, Dowdy SF. 2002. Protein transduction technology. Curr Opin Biotechnol 13:52-56.
73. Wadia JS, Stan RV, Dowdy SF. 2004. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315.
74. Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, Zhuo M. 2001. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci 4:164-169.
75. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 97:13003-13008.
76. Yoshikawa T, Sugita T, Mukai Y, Yamanada N, Nagano K, Nabeshi H, Yoshioka Y, Nakagawa S, Abe Y, Kamada H, Tsunoda S, Tsutsumi Y. 2008. Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for Peptide aptamer delivery into the nucleus. J Mol Biol 380:777-782.
77. Zhang XY, Dinh A, Cronin J, Li SC, Reiser J. 2008. Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain. J Neurochem 104:1055-1064.
78. Zhou Y, Du W, Koretsky T, Bagby GC, Pang Q. 2008. TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 112:2474-2483.
79. Ziegler A, Seelig J. 2004. Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys J 86:254-263. (Pubitemid 38067453)